Key Takeaways
- • Function Health, a health testing platform, raised $450 million in growth financing from venture firm General Catalyst, according to Private Equity International, with reports dated July 2026.
- • Function provides access to more than 100 blood tests through an annual subscription, priced at $365 per year according to NextMD.
- • One General Catalyst profile describes the financing as debt and says it brings Function's total funding to $804 million, though this figure could not be independently verified.
- • The financing is intended to scale Function's tech-enabled preventive health platform.
Summary
Health testing platform Function has secured $450 million in growth financing from General Catalyst, according to Private Equity International. The company offers access to more than 100 blood tests for a yearly subscription, which NextMD reports costs $365 per year. The capital is intended to scale Function's tech-enabled preventive health platform.
A General Catalyst-related profile characterizes the transaction as debt financing and states that it raises Function's total funding to $804 million. The full terms, valuation, and investor syndicate were not available in the sources reviewed, so the structure of the instrument should be treated as reported rather than confirmed.
The deal reflects continued venture and growth-stage capital directed at consumer-facing preventive diagnostics, where subscription-based access to laboratory testing is the core model. Investors tracking the segment will likely watch Function's pricing against competitors such as Superpower, which NextMD cites in its comparison.
A General Catalyst-related profile characterizes the transaction as debt financing and states that it raises Function's total funding to $804 million. The full terms, valuation, and investor syndicate were not available in the sources reviewed, so the structure of the instrument should be treated as reported rather than confirmed.
The deal reflects continued venture and growth-stage capital directed at consumer-facing preventive diagnostics, where subscription-based access to laboratory testing is the core model. Investors tracking the segment will likely watch Function's pricing against competitors such as Superpower, which NextMD cites in its comparison.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.